{"Clinical Trial ID": "NCT01783444", "Intervention": ["INTERVENTION 1:", "Everolimus 10 mg + Exemestane 25 mg", "Everolimus (10 mg daily) with Exemestane (25 mg daily) (control arm).", "INTERVENTION 2:", "Everolimus 10 mg", "Everolimus (10 mg per day) (survey arm)."], "Eligibility": ["Key Inclusion Criteria:", "- Women with locally advanced, recurrent or metastatic breast cancer, as well as confirmation of a positive estrogen-receptor (ER+). Measurable disease defined as at least one injury 10 mm per CT or MRI that can be accurately measured in at least one dimension (scanning strip thickness 5 mm) OR Bone lesions: lytic or mixed (lytic + blast) in the absence of measurable disease as defined above.", "Key Exclusion Criteria:", "Patients who have received more than one chemotherapy line Patients with only unmeasurable lesions other than lytic or mixed bone metastases (lytics and blasts)."], "Results": ["Performance measures:", "- Everolimus Plus Exemestane versus Everolimus Alone", "If a patient did not have an event, the SSP was censored at the time of the last appropriate tumour assessment. SSP was compared between the combined treatment with everolimus + exemestane and the monotherapy with everolimus.", "Delay: Date of randomization until the date of the first documented tumour progression or death of any cause, whichever occurs first, reported between the day of the first randomised patient up to 39 months", "Results 1:", "Title of the arm/group: Everolimus 10 mg + Exemestane 25 mg", "Description of the arm/group: Everolimus (10 mg daily) with Exemestane (25 mg daily) (control arm).", "Total number of participants analysed: 104", "Median (90% confidence interval)", "Unit of measure: Month 8.41 (6.60 to 9.72)", "Results 2:", "Title of arm/group: Everolimus 10 mg", "Description of the arm/group: Everolimus (10 mg per day) (survey arm).", "Total number of participants analysed: 103", "Median (90% confidence interval)", "Unit of measure: Month 6.77 (5.52-7.20)"], "Adverse Events": ["Undesirable Events 1:", "Total: 37/104 (35.58 per cent)", "Anemia 1/104 (0.96%)", "Febrile neutropenia 0/104 (0.00 %)", "Leucopenia 0/104 (0.00 %)", "Neutropenia 0/104 (0.00 %)", "Pancytopenia 0/104 (0.00 %)", "Thrombocytopenia 0/104 (0.00 %)", "Atrial fibrillation 1/104 (0.96%)", "Cardiac arrest 1/104 (0.96%)", "Heart failure 1/104 (0.96%)", "Acute heart failure 1/104 (0.96%)", "- Congestive heart failure 0/104 (0.00 %)", "Adverse Events 2:", "Total: 30/103 (29.13 per cent)", "Anemia 3/103 (2.91%)", "Febrile neutropenia 0/103 (0.00 %)", "- Leucopenia 0/103 (0.00 %)", "Neutropenia 0/103 (0.00 %)", "Pancytopenia 0/103 (0.00 %)", "Thrombocytopenia 0/103 (0.00 %)", "Atrial fibrillation 0/103 (0.00 %)", "Cardiac arrest 0/103 (0.00 %)", "- Heart failure 0/103 (0.00 %)", "Acute heart failure 0/103 (0.00 %)", "Congestive heart failure 1/103 (0.97%)"]}